Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HES Flare: GSK's Nucala Edges Forward

Marketing Submissions Expected In 2020

Executive Summary

GlaxoSmithKline’s interleukin-5 inhibitor, Nucala (mepolizumab), is the first treatment shown to reduce the hypereosinophilic syndrome flare-ups in a 100-patient pivotal study.

You may also be interested in...



Keeping Track: New Nucala Indication; BMS’ Ide-Cel Clears Filing Hurdle; First Applications From Telix And ADC Therapeutics

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

GSK Has High Hopes For COPD Vaccine

By combining its expertise in respiratory and vaccines, the UK drugs giant could have a potential blockbuster for chronic obstructive pulmonary disease, which is expected to become the third leading cause of death worldwide by the end of the decade.

AstraZeneca: Don’t Write Off Fasenra In COPD Just Yet

AstraZeneca's R&D leader admits mistakes in earlier failed Phase III trials. A new study will target the high eosinophil sub-group.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel